Slide 1: Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in r/r LBCL
Phase 1 Results with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL) Locke FL1, Lekakis LJ2, Eradat HA3, Munoz J4, Tees M5, de Vos S6, Nath R7, Stevens DA8, Malik SA9, Popplewell LL10, Hamadani M11, Oluwole OO12, Perales M-A13, Miklos DB14, Fisher PW1
Slide 2: Background on ALLO-501 & ALLO-501A
Background on ALLO-501 & ALLO-501A • ALLO-501A is an HLA-unmatched, off-the-shelf, anti-CD19 allogeneic CAR T cell product administered as a one-time treatment that is capable of inducing durable remissions in r/r LBCL patients. ALLO-501 is similar to ALLO-501A except for the inclusion of a rituxima
Slide 3: Baseline Characteristics of Subgroup & Phase 1 and Subgroup Safety Results
Baseline Characteristics of Subgroup & Phase 1 and Subgroup Safety Results • 12 patients were included in the subgroup • No Gr≥3 CRS or ICANS events • 3 days from enrollment to treatment initiation (median) • No GvHD events • 100% of patients received product per product specs Baseline Characteristi
Slide 4: Efficacy Results for Patients Treated With Phase 2 Regimen
Efficacy Results for Patients Treated With Phase 2 Regimen Swimmer Plot of Tumor Response Response Rates N=12 ORR, n (%) 8 (67) CR, n (%) 7 (58) 6 months CRa, n (%) 5 (42) a Analysis of patients who had the opportunity to be followed through Month 6 or experienced disease progression prior to Month
Slide 5: Conclusions
Conclusions 1. A single dose of ALLO-501/ALLO-501A following FCA90 provided durable remissions up to 31+ months that compared favorably to outcomes achieved with autologous CAR T cell therapies in patients with r/r LBCL. 2. ALLO-501/ALLO-501A following FCA90 was generally well tolerated with no Gr≥3